The Promise of CGRP Antibodies to Change Practice in Migraine Treatment
Release Date: July 26, 2018
Expiration Date: July 26, 2019
Expected time to complete this activity as designed: 90 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, the faculty will cover today’s clinical environment and the challenges associated with the recognition and management of episodic and chronic migraine, and with the effective preventive treatment and prophylaxis of these headache disorders. Dr. Lipton, Dr. Charles, and Dr. Dodick will also highlight the challenges currently encountered by patients and clinicians when implementing preventive treatment for migraine and share the promising new therapies on the horizon and how they compare with currently available therapies. This e-Monograph will include insights and understanding about how these new therapies work, the unique features of the CGRP monoclonal antibodies, how these four new agents have performed in clinical trials and most importantly how they may impact practice.
This activity is designed for multidisciplinary healthcare providers in the community setting, including primary care physicians, nurses, pharmacists and other allied healthcare professionals who provide care to patients with headache disorder.
Upon completion of this educational activity, participants should be able to:
- Identify the unmet clinical needs resulting from ineffective prevention of migraine
- Describe the role of calcitonin gene-related peptides (CGRPs) in the pathophysiology of migraine
- Compare and contrast emerging treatments currently in clinical trials which show promise to improve patient outcomes in the preventive treatment of episodic and chronic migraine
The Science of Migraine: Pathophysiology – Andrew C. Charles, MD
Calcitonin Gene-Related Peptide and Migraine – David W. Dodick, MD
Preventive Prophylaxis for Migraine – Richard B. Lipton, MD
Instructions for Participation and Credit
This activity is eligible for credit through July 26, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Andrew C. Charles, MD
Professor of Neurology
UCLA School of Medicine
Los Angeles, California
Dr. Andrew Charles received his medical degree from the University of California, Los Angeles (UCLA). He completed his neurology residency training and did a neuropharmacology research fellowship at UCLA before joining the faculty full-time in 1992. Dr. Charles is currently a Professor of Neurology at the UCLA School of Medicine, where he holds the Meyer and Renee Luskin Chair in Migraine and Headache Studies. He is also Director of the UCLA Goldberg Migraine Program, which includes basic and clinical research, education, and care of patients with headache disorders. His laboratory focuses on cellular and pharmacological mechanisms of migraine and pain, with a particular interest in the development of novel therapies. Dr. Charles is an associate editor of the journal Cephalalgia, and he has served on the Board of Trustees of the International Headache Society. He currently holds the position of Secretary of the American Headache Society.
David W. Dodick, MD
Professor of Neurology
Mayo Clinic College of Medicine
Dr. David Dodick is a Professor of Neurology at the Mayo Clinic College of Medicine and a consultant in neurology at the Mayo Clinic in Scottsdale, Arizona, as well as the Past-President of the American Headache Society. He is the Program Director of the Mayo Clinic Neurology Residency Program and Headache Medicine Fellowship Program, and the Director of the Headache Program and the Sports Neurology and Concussion Program at Mayo Clinic in Arizona.
In addition, Dr. Dodick is an Adjunct Professor and International Chair of Headache in the Department of Neurosciences, Norwegian University of Science and Technology. Dr. Dodick is also President of the International Headache Society, and Chair of the American Migraine Foundation.
Richard B. Lipton, MD
Professor of Neurology
Professor of Epidemiology and Population Health
Professor of Psychiatry and Behavioral Sciences
Albert Einstein College of Medicine
Bronx, New York
Dr. Richard Lipton received his medical degree from the University of Chicago Pritzker School of Medicine. He completed an internal medicine residency at Northwestern University Hospital, and a neurology residency/chief residency at Albert Einstein College of Medicine. In addition, he completed a fellowship in clinical neurophysiology and epilepsy at Albert Einstein, and a fellowship in neuroepidemiology at Sergievsky Center, Columbia University. Dr. Lipton is Professor of Neurology, Professor of Epidemiology and Population Health, and Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine. In addition, he is their Vice Chair of Neurology, the Edwin S. Lowe Chair in Neurology, and Director, Division of Cognitive Aging and Dementia. Dr. Lipton is also Director of the Headache Center and a Staff Neurologist in the Headache Unit, Montefiore Medical Center, and an Associate Research Scientist at the Sergievsky Center.
Dr. Lipton is a diplomate of the National Board of Medical Examiners, and is board certified by the American Board of Psychiatry and Neurology (Neurology), and in Headache Medicine (UCNS). He is on the Long-term Planning Committee, American Association for the Study of Headache; American Headache Society Board of Directors; and a Fellow of the American Neurological Association and the American Academy of Neurology. Dr. Lipton also holds memberships in the American Academy of Neurology, American Headache Society, American Neurological Association, American Society for Clinical Pharmacology and Therapeutics, American Society for Neurologic Investigation, International Headache Society, and the World Federation of Neurology. He is a consultant/reviewer for dozens of peer-reviewed journals and is on the editorial board of Cephalalgia, Journal of Headache and Pain, and Neurology, and is associate editor of Headache Currents, and Cephalalgia. In addition, Dr. Lipton has published more than 700 abstracts, letters and scientific presentations, 685 original communications, 190 chapters and review articles, and 13 books.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-003-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours. Program Number: 18-003-072
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Andrew Charles has received honoraria as a consultant from Alder BioPharmaceuticals Inc., Amgen Inc., Biohaven Pharmaceuticals, Eli Lilly and Company, and eNeura Inc. He has received grant support related to research activities from Takeda Oncology.
Dr. David Dodick has received honoraria as a consultant from Acorda, Alder BioPharmaceuticals Inc., Allergan, Inc., Amgen Inc., Autonomic Technologies, Inc., Biocentric Health, Biohaven Pharmaceuticals, Boston Scientific Corporation, CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, eNeura Inc., GBS Ventures, Insys Therapeutics, Inc., Magellan BioScience Group, Inc., Merck & Co., Inc., Pfizer Inc., Promius Pharma, LLC., TEVA Pharmaceutical LTD, Tonix Pharmaceuticals Holding Corp., Trigemina, Inc., Xenon Pharmaceuticals Inc., and Zosano Pharma Corporation. He has received royalties from Cambridge University Press and Oxford University Press. Dr. Dodick has stock options with EPIEN Medical, Inc., GBS/Nocira, and Mobile Health, and has a consulting use agreement with NAS. He holds a board position at King-Devick Technologies, Inc.
Dr. Richard Lipton has served as a consultant, advisory board member, or has received honoraria from the American Academy of Neurology, Alder BioPharmaceuticals Inc., Allergan, Inc., American Headache Society, Amgen Inc., Autonomic Technologies, Inc., Avanir Pharmaceuticals, Inc., Biohaven Pharmaceuticals, BioVision Inc., Boston Scientific Corporation, CoLucid Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura Inc., GlaxoSmithKline plc, Merck & Co., Inc., PERNIX Therapeutics, Pfizer Inc., Supernus Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd., Trigemina, Inc., Vector Pharma, and Vedanta Biosciences, Inc. He has received grant support related to research activities from the National Institutes of Health (NIH), Migraine Research Foundation, and the National Headache Foundation. He has also received royalties from Wolff’s Headache, Oxford University Press, Wiley, and Informa. He owns stock options in eNeura Therapeutics and Biohaven Holdings.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Teva Pharmaceuticals
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.